The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.
Today, the Cystic Fibrosis Foundation awarded $2.76 million for 11 laboratory studies that will advance our understanding of the underlying factors that impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.
|
5 min read
Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment
|
3 min read
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
|
3 min read